174 related articles for article (PubMed ID: 32301021)
1. Hepatobiliary Adverse Events.
Abu-Sbeih H; Wang Y
Adv Exp Med Biol; 2020; 1244():271-276. PubMed ID: 32301021
[TBL] [Abstract][Full Text] [Related]
2. Hepatobiliary and Pancreatic Adverse Events.
Zhang HC; Wang LS; Miller E
Adv Exp Med Biol; 2021; 1342():339-355. PubMed ID: 34972973
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibitors-Induced Hepatitis.
Tian Y; Abu-Sbeih H; Wang Y
Adv Exp Med Biol; 2018; 995():159-164. PubMed ID: 30539511
[TBL] [Abstract][Full Text] [Related]
4. Type 3 autoimmune pancreatitis (immune checkpoint inhibitor-induced pancreatitis).
Sayed Ahmed A; Abreo M; Thomas A; Chari ST
Curr Opin Gastroenterol; 2022 Sep; 38(5):516-520. PubMed ID: 35881977
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury.
Abu-Sbeih H; Tang T; Lu Y; Thirumurthi S; Altan M; Jazaeri AA; Dadu R; Coronel E; Wang Y
J Immunother Cancer; 2019 Feb; 7(1):31. PubMed ID: 30728076
[TBL] [Abstract][Full Text] [Related]
6. Pancreatitis and Hyperlipasemia in the Setting of Immune Checkpoint Inhibitor Therapy.
Townsend MJ; Liu M; Giobbie-Hurder A; Sack JS; LeBoeuf NR; Hodi FS; McNabb-Baltar J; Grover S
J Natl Compr Canc Netw; 2023 Aug; 21(8):831-840.e3. PubMed ID: 37549912
[TBL] [Abstract][Full Text] [Related]
7. Incidence of Pancreatic Injury and Pancreatitis in Patients Treated With Immune Checkpoint Inhibitors.
Hori Y; Naitoh I; Naiki-Ito A; Kawai T; Yoshida M; Kato A; Kachi K; Sahashi H; Adachi A; Toyohara T; Kito Y; Yamamoto T; Takahashi S; Kataoka H
Clin Transl Gastroenterol; 2024 Apr; 15(4):e00667. PubMed ID: 38088372
[TBL] [Abstract][Full Text] [Related]
8. Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis.
George J; Bajaj D; Sankaramangalam K; Yoo JW; Joshi NS; Gettinger S; Price C; Farrell JJ
Pancreatology; 2019 Jun; 19(4):587-594. PubMed ID: 31076344
[TBL] [Abstract][Full Text] [Related]
9. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
10. Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies.
Jennings JJ; Mandaliya R; Nakshabandi A; Lewis JH
Expert Opin Drug Metab Toxicol; 2019 Mar; 15(3):231-244. PubMed ID: 30677306
[TBL] [Abstract][Full Text] [Related]
11. Acute pancreatitis without abdominal pain induced by administration of nivolumab and ipilimumab.
Yamamoto K; Oka K; Son R; Honda H; Sakae H; Hasegawa K; Horiguchi S; Kato H; Yamasaki O; Otsuka F
Mod Rheumatol Case Rep; 2021 Jul; 5(2):425-430. PubMed ID: 33821775
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic injury in patients treated with immune checkpoint inhibitors: a retrospective multicenterstudy.
Nagao K; Sakai A; Tsumura H; Iemoto T; Hirata Y; Hori H; Ogisu K; Kakuyama S; Ikegawa T; Hirata T; Ezaki T; Furumatsu K; Yamanaka K; Kato T; Fujigaki S; Tanaka H; Yagi Y; Tanaka T; Kobayashi T; Masuda A; Shiomi H; Kodama Y
J Gastroenterol; 2024 May; 59(5):424-433. PubMed ID: 38421473
[TBL] [Abstract][Full Text] [Related]
13. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents.
Suzman DL; Pelosof L; Rosenberg A; Avigan MI
Liver Int; 2018 Jun; 38(6):976-987. PubMed ID: 29603856
[TBL] [Abstract][Full Text] [Related]
14. Checkpoint inhibitor hepatotoxicity: pathogenesis and management.
Cunningham M; Gupta R; Butler M
Hepatology; 2024 Jan; 79(1):198-212. PubMed ID: 36633259
[TBL] [Abstract][Full Text] [Related]
15. Clinical Characteristics of ICI-Related Pancreatitis and Cholangitis Including Radiographic and Endoscopic Findings.
Nakano R; Shiomi H; Fujiwara A; Yoshihara K; Yoshioka R; Kawata S; Ota S; Yuri Y; Takashima T; Aizawa N; Ikeda N; Nishimura T; Enomoto H; Iijima H
Healthcare (Basel); 2022 Apr; 10(5):. PubMed ID: 35627900
[TBL] [Abstract][Full Text] [Related]
16. Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors.
Gkiozos I; Kopitopoulou A; Kalkanis A; Vamvakaris IN; Judson MA; Syrigos KN
J Thorac Oncol; 2018 Aug; 13(8):1076-1082. PubMed ID: 29763666
[TBL] [Abstract][Full Text] [Related]
17. Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology.
Hercun J; Vincent C; Bilodeau M; Lapierre P
Front Immunol; 2022; 13():907591. PubMed ID: 35844534
[TBL] [Abstract][Full Text] [Related]
18. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen.
Cappelli LC; Brahmer JR; Forde PM; Le DT; Lipson EJ; Naidoo J; Zheng L; Bingham CO; Shah AA
Semin Arthritis Rheum; 2018 Dec; 48(3):553-557. PubMed ID: 29573850
[TBL] [Abstract][Full Text] [Related]
19. Hepatobiliary and pancreatic manifestations in inflammatory bowel diseases: a referral center study.
Fousekis FS; Katsanos KH; Theopistos VI; Baltayiannis G; Kosmidou M; Glantzounis G; Christou L; Tsianos EV; Christodoulou DK
BMC Gastroenterol; 2019 Apr; 19(1):48. PubMed ID: 30943899
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitor-related hepatotoxicity: A review.
Remash D; Prince DS; McKenzie C; Strasser SI; Kao S; Liu K
World J Gastroenterol; 2021 Aug; 27(32):5376-5391. PubMed ID: 34539139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
